Expanding Ampyra's Reach? Studies In Other Neurological Conditions Have Stumbled, But Acorda Has Not Ruled Out Future Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The fampridine molecule has been used as a pharmacy compounded product for a variety of neurological conditions based on its mechanism of action. In animal studies, the drug "has been shown to increase conduction of nerve signals in demyelinated axons through blocking of potassium channels," Acorda observed in its annual 10-K filing on Feb. 26.
You may also be interested in...
Everything Old Is New Again: History Of Compounding Shaped Ampyra REMS
Acorda’s Ampyra (dalfampridine) is a first-in-class new molecular entity in terms of FDA approval, but the drug substance’s history as a compounded drug raised the concerns necessitating a Risk Evaluation and Mitigation Strategy, FDA’s review documents show.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product